Finance

Exclusive: WHO experts voice “very low confidence” in some Sinopharm COVID-19 vaccine data By Reuters

© Reuters. FILE PHOTO: A nurse holds a vial of China’s Sinopharm coronavirus disease (COVID-19) vaccine at a health center in Caracas, Venezuela March 7, 2021. REUTERS/Leonardo Fernandez Viloria/File Photo

By Stephanie Nebehay

GENEVA (Reuters) – WHO experts have voiced “very low confidence” in data provided by Chinese state-owned drugmaker Sinopharm on its COVID-19 vaccine regarding the risk of serious side-effects in some patients, but overall confidence in its ability to prevent the disease, a document seen by Reuters shows.

There was no immediate reply from the World Health Organization to a query about any concerns linked to the Sinopharm vaccine, BBIBP-CorV. In Beijing, Sinopharm was not immediately reachable for comment outside working hours.

The “evidence assessment” document was prepared by the WHO’s Strategic Advisory Group of Experts (SAGE) for its review scheduled this week of the Sinopharm shot, authorised by 45 countries and jurisdictions for use in adults, with 65 million doses administered. The experts review evidence and give recommendations on policy and dosages associated with a vaccine.

The document includes summaries of data from clinical trials in China, Bahrain, Egypt, Jordan and the United Arab Emirates.

Vaccine efficacy in multi-country Phase 3 clinical trials was 78.1% after two doses, the document said. This was a slight drop from 79.34% announced previously in China.

“We are very confident that 2 doses of BBIBP-CorV are efficacious in preventing PCR confirmed COVID19 in adults (18-59 years),” the document said.

But it added: “Analysis of safety amongst participants with comorbidities (was) limited by the low number of participants with comorbidities (other than obesity) in the Phase 3 trial.”

Among “evidence gaps”, it cited data on protection against severe disease, duration of protection, safety for use in pregnant women and in older adults and identification/evaluation of rare adverse events through post-authorisation safety monitoring.

“We have very low confidence in the quality of evidence that the risk of serious adverse events following one or two doses of BBIBP-CorV in older adults (≥60 years) is low,” it said.

“We have very low confidence in the quality of evidence that the risk of serious adverse events in individuals with comorbidities or health states that increase risk for severe COVID-19 following one or two doses of BBIBP-CorV is low,” it added.

The SAGE analysis was prepared as a WHO technical advisory group currently reviews the vaccine for an emergency use approval, which would not only pave the way for its use in the global COVAX vaccine sharing platform but also provide a crucial international endorsement for a vaccine developed in China.

A WHO spokesman said that a decision on the listing was not expected on Wednesday.

(Reporting and writing by Stephanie Nebehay in Geneva; additional reporting by Cheng Leng in Beijing; editing by Miyoung Kim and Nick Macfie)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button